Answers are grounded in this paper and cite their sources.
The maximum-tolerated dose and recommended phase II dose of bortezomib in this schedule is 1.6 mg/m(2). Biologic activity (inhibition of nuclear factor-kappa B-related markers) and antitumor activity is seen in AIPCa at tolerated doses of bortezomib. This agent should be further explored with chemotherapy agents in advanced prostate cancer.
No takes yet. Share an insight, caveat, or question.
Papandreou et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: